Poshuvet Duo Sustained Release Tablet 5/1000 mg
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
MFDS item code 202107130 · Approved 2021.10.26
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is administered in conjunction with dietary and exercise therapy to help control blood sugar in adult patients with type 2 diabetes using dapagliflozin and metformin together. It is particularly suitable for patients with insufficient blood sugar control who have cardiovascular disease or risk factors. Please ensure to refer to the precautions regarding the occurrence of cardiovascular events upon administration. This medication effectively regulates blood sugar and improves the patient's health management.
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, given as 2 tablets of 5mg/1000mg. Patients who have not previously received pharmacologic treatment for diabetes and whose blood glucose is not adequately controlled with monotherapy: When used as initial therapy in patients who have not previously received pharmacologic treatment for diabetes, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions to metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the patient's current metformin dose or an appropriately adjusted dose therapeutically close to it. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, treatment may be started at the doses of dapagliflozin and metformin previously being taken. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other glucose-lowering medicines. Because such a change may cause alterations in blood glucose control, any changes in the treatment of patients with type 2 diabetes should be made with careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary for patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted through the kidneys and renal function is more likely to decline in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Use in Elderly Patients).
This medication is used for the treatment of diabetes and helps with blood sugar control. It may rarely cause a serious condition known as lactic acidosis, which can result in dangerous situations due to excessive accumulation of lactic acid in the body, thus caution is necessary. When taken with other diabetes medications, hypoglycemia may occur, so attention to symptoms is required. Patients with poor kidney function, dehydration, severe infections, heart issues, or liver dysfunction should not use this medication. Patients who are about to undergo surgery or are scheduled to use radiological contrast agents should temporarily discontinue this medication and should restart it only after confirming normal kidney function. Women who are pregnant or breastfeeding should refrain from using this medication for safety. Elderly patients or those with compromised kidney function should regularly monitor their kidney function before and after taking this medication and should be cautious for symptoms of hypotension or fluid deficiency. This medication may increase the risk of genital infections or urinary tract infections, so if related symptoms arise, immediate consultation with healthcare professionals is necessary. Vitamin B12 deficiency may occur; therefore, it is advisable to periodically check vitamin B12 levels during prolonged use. Excessive alcohol consumption should be avoided, and during the use of this medication, any interactions with other drugs that may affect blood sugar control should be discussed with a physician. During the use of this medication, dizziness or symptoms of hypoglycemia may occur, so caution is required when driving or operating machinery. Keep out of the reach of children and store in the original container to maintain the quality of the medication.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air or moisture. It is recommended to maintain a storage temperature between 1 degrees Celsius and 30 degrees Celsius.
A pink, double convex, egg-shaped film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK Inno.N Co., Ltd.
CombinationDapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK inno.N Co., Ltd.
Dapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Poonglim Pharmaceutical Co., Ltd.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Punglim Muhak Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
KS Pharm Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.